Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5KYPJ)

Drug Name
Butorphanol Drug Info
Synonyms
Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
Therapeutic ClassAnalgesics
Cross-matching ID
PubChem CID
5361092
ChEBI ID
CHEMBL33986
CAS Number
CAS 42408-82-2
TTD Drug ID
D0X9RG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Staphylococcus aureus infection 2.05 1.86e-2 72/95 (75.79%) KRT17;FPR1;HLA-DRB1;...
Asthma 2.05 9.32e-3 25/31 (80.65%) FCER1G;CD40;HLA-DRB1;...
Viral protein interaction with cytokine and cytokine re... 2.05 6.21e-3 84/100 (84%) TNFSF10;CXCL5;CCL4;...
Leishmaniasis 1.95 1.40e-2 67/77 (87.01%) NCF2;CYBB;HLA-DRB1;...
Pertussis 1.94 1.30e-2 64/76 (84.21%) GNAI1;CXCL5;CD14;...
Phagosome 1.94 1.09e-2 118/152 (77.63%) NCF2;CYBB;COMP;...
Systemic lupus erythematosus 1.93 9.32e-3 45/135 (33.33%) CD40;HLA-DRB1;HLA-DRA;...
Inflammatory bowel disease 1.88 9.32e-3 58/65 (89.23%) HLA-DRB1;HLA-DRA;HLA-DQA1;...
Retinol metabolism 1.85 1.24e-2 41/68 (60.29%) CYP2A6;CYP1A1;DHRS9;...
Metabolism of xenobiotics by cytochrome P450 1.84 1.40e-2 49/77 (63.64%) HSD11B1;CYP1B1;GSTO1;...
Cytokine-cytokine receptor interaction 1.82 1.44e-2 246/295 (83.39%) TNFSF10;CXCL5;INHBA;...
Linoleic acid metabolism 1.80 1.55e-2 21/29 (72.41%) PLA2G2A;PLA2G5;ALOX15;...
Steroid hormone biosynthesis 1.80 1.43e-2 43/61 (70.49%) HSD11B1;CYP1B1;CYP1A1;...
Allograft rejection 1.80 1.33e-2 32/38 (84.21%) CD40;HLA-DRB1;HLA-DRA;...
Autoimmune thyroid disease 1.80 1.24e-2 46/53 (86.79%) CD40;HLA-DRB1;HLA-DRA;...
Tuberculosis 1.78 1.34e-2 159/180 (88.33%) CASP10;CTSS;FCER1G;...
Legionellosis 1.78 1.26e-2 51/57 (89.47%) NFKB2;CD14;CXCL3;...
Viral myocarditis 1.77 1.29e-2 53/60 (88.33%) CD40;HLA-DRB1;HLA-DRA;...
IL-17 signaling pathway 1.73 1.62e-2 84/94 (89.36%) MMP1;CXCL5;MMP3;...
Complement and coagulation cascades 1.72 1.68e-2 76/85 (89.41%) F13A1;PLAU;F2R;...
Rheumatoid arthritis 1.72 1.64e-2 78/93 (83.87%) MMP1;CXCL5;MMP3;...
Type I diabetes mellitus 1.71 1.61e-2 38/43 (88.37%) HLA-DRB1;PTPRN2;HLA-DRA;...
Intestinal immune network for IgA production 1.65 3.24e-2 38/48 (79.17%) CD40;HLA-DRB1;HLA-DRA;...
Protein digestion and absorption 1.65 3.11e-2 78/103 (75.73%) COL10A1;CPB1;COL5A2;...
Arachidonic acid metabolism 1.64 3.24e-2 48/61 (78.69%) PLA2G2A;ALOX5;PTGS2;...
Coronavirus disease 1.62 3.37e-2 215/232 (92.67%) MMP1;F13A1;MMP3;...
Hematopoietic cell lineage 1.61 3.48e-2 90/99 (90.91%) CD1E;HLA-DRB1;CD1B;...
Graft-versus-host disease 1.60 4.19e-2 32/42 (76.19%) HLA-DRB1;HLA-DRA;HLA-DQA1;...
C-type lectin receptor signaling pathway 1.59 4.50e-2 93/104 (89.42%) NFKB2;PAK1;RELB;...
Osteoclast differentiation 1.59 4.41e-2 117/127 (92.13%) NFKB2;NCF2;RELB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H